Literature DB >> 9771900

Expression of type VI adenylyl cyclase in the central nervous system: implication for a potential regulator of multiple signals in different neurotransmitter systems.

F C Liu1, G C Wu, S T Hsieh, H L Lai, H F Wang, T W Wang, Y Chern.   

Abstract

The aim of this study was to investigate the distribution of a calcium-inhibitable adenylyl cyclase type VI (type VI AC) in the central nervous system using an antiserum directed against the N-terminus of type VI AC. Our results indicate that type VI AC immunoreactivity is generally expressed in many brain regions with different levels of intensity. Most interestingly, the majority of the detected type VI AC immunoreactivity is present in cells of neuronal phenotype. Double immunostaining of type VI AC and markers of various neurotransmitter systems suggest that type VI AC might participate in regulation of the classical neurotransmitter systems and therefore appeared to play a very important role in the central nervous system.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9771900     DOI: 10.1016/s0014-5793(98)01098-9

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  12 in total

1.  Functional uncoupling of adenosine A(2A) receptors and reduced responseto caffeine in mice lacking dopamine D2 receptors.

Authors:  N R Zahniser; J K Simosky; R D Mayfield; C A Negri; T Hanania; G A Larson; M A Kelly; D K Grandy; M Rubinstein; M J Low; B B Fredholm
Journal:  J Neurosci       Date:  2000-08-15       Impact factor: 6.167

2.  Impaired D2 dopamine receptor function in mice lacking type 5 adenylyl cyclase.

Authors:  Ko-Woon Lee; Jang-Hee Hong; In Young Choi; Yongzhe Che; Ja-Kyeong Lee; Sung-Don Yang; Chang-Woo Song; Ho Sung Kang; Jae-Heun Lee; Jai Sung Noh; Hee-Sup Shin; Pyung-Lim Han
Journal:  J Neurosci       Date:  2002-09-15       Impact factor: 6.167

3.  Cellular localisation of adenylyl cyclase: a post-genome perspective.

Authors:  Ferenc A Antoni; Ulrich K Wiegand; Jamie Black; James Simpson
Journal:  Neurochem Res       Date:  2006-02       Impact factor: 3.996

4.  Regulation of feedback between protein kinase A and the proteasome system worsens Huntington's disease.

Authors:  Jiun-Tsai Lin; Wei-Cheng Chang; Hui-Mei Chen; Hsing-Lin Lai; Chih-Yeh Chen; Mi-Hua Tao; Yijuang Chern
Journal:  Mol Cell Biol       Date:  2012-12-28       Impact factor: 4.272

5.  Type VI adenylyl cyclase regulates neurite extension by binding to Snapin and Snap25.

Authors:  Chia-Shan Wu; Jiun-Tsai Lin; Chen-Li Chien; Wei-Cheng Chang; Hsing-Lin Lai; Ching-Pang Chang; Yijuang Chern
Journal:  Mol Cell Biol       Date:  2011-10-10       Impact factor: 4.272

6.  GABA inhibition of immortalized gonadotropin-releasing hormone neuronal excitability involves GABA(A) receptors negatively coupled to cyclic adenosine monophosphate formation.

Authors:  L Beltrán-Parrazal; G Noris; C Clapp; G Martínez de la Escalera
Journal:  Endocrine       Date:  2001-03       Impact factor: 3.633

7.  Cyclic nucleotide-mediated regulation of hippocampal mossy fiber development: a target-specific guidance.

Authors:  S Mizuhashi; N Nishiyama; N Matsuki; Y Ikegaya
Journal:  J Neurosci       Date:  2001-08-15       Impact factor: 6.167

8.  Ginsenoside compound K reduces the progression of Huntington's disease via the inhibition of oxidative stress and overactivation of the ATM/AMPK pathway.

Authors:  Kuo-Feng Hua; A-Ching Chao; Ting-Yu Lin; Wan-Tze Chen; Yu-Chieh Lee; Wan-Han Hsu; Sheau-Long Lee; Hsin-Min Wang; Ding-I Yang; Tz-Chuen Ju
Journal:  J Ginseng Res       Date:  2021-11-11       Impact factor: 5.735

9.  A new drug design targeting the adenosinergic system for Huntington's disease.

Authors:  Nai-Kuei Huang; Jung-Hsin Lin; Jiun-Tsai Lin; Chia-I Lin; Eric Minwei Liu; Chun-Jung Lin; Wan-Ping Chen; Yuh-Chiang Shen; Hui-Mei Chen; Jhih-Bin Chen; Hsing-Lin Lai; Chieh-Wen Yang; Ming-Chang Chiang; Yu-Shuo Wu; Chen Chang; Jiang-Fan Chen; Jim-Min Fang; Yun-Lian Lin; Yijuang Chern
Journal:  PLoS One       Date:  2011-06-21       Impact factor: 3.240

10.  Nuclear translocation of AMPK-alpha1 potentiates striatal neurodegeneration in Huntington's disease.

Authors:  Tz-Chuen Ju; Hui-Mei Chen; Jiun-Tsai Lin; Ching-Pang Chang; Wei-Cheng Chang; Jheng-Jie Kang; Cheng-Pu Sun; Mi-Hua Tao; Pang-Hsien Tu; Chen Chang; Dennis W Dickson; Yijuang Chern
Journal:  J Cell Biol       Date:  2011-07-18       Impact factor: 10.539

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.